Kivizidiale

Timolol and Travoprost, the active ingredients in Kivizidiale, are a beta blocker/prostaglandin analog combination presented as ocular drops for ophthalmic use. It treats primary open-angle glaucoma and ocular hypertension by lowering intra‑ocular pressure. GNH USA supplies Kivizidiale as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kivizidiale is used in the management of glaucoma and related ocular pressure disorders. - Primary open-angle glaucoma: reduces intra‑ocular pressure to slow disease progression. - Ocular hypertension: lowers eye pressure to prevent development of glaucoma. - Post‑surgical pressure control: maintains target pressure after laser or surgical procedures.

Common Side Effects: - Eye irritation or burning sensation: mild discomfort after instillation. - Blurred vision: transient visual disturbance. - Redness of the eye: conjunctival hyperemia. - Dry eye: reduced tear production. - Foreign body sensation: feeling of grit. - Ocular discomfort: mild itching or stinging.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, rash, or difficulty breathing. - Eyelid swelling: significant edema around the lid. - Persistent eye pain: prolonged discomfort requiring medical review. - Vision loss: sudden decrease in visual acuity. - Systemic beta‑blocker effects: bradycardia, hypotension, or bronchospasm.

Before using Kivizidiale, consider the following precautions. - Monitor intra‑ocular pressure: assess pressure after initiation and adjust therapy as needed. - Assess cardiovascular status: use cautiously in patients with bradycardia, heart block, or asthma. - Avoid concurrent beta‑blocker eye drops: duplication may increase systemic exposure. - Review systemic beta‑blocker therapy: inform ophthalmologist of any oral beta‑blocker use. - Pregnancy and lactation: use only if clearly needed after risk‑benefit evaluation. - Store at room temperature: keep in the original container, protect from light and moisture.

Kivizidiale may interact with other medications. Major Interactions (Avoid): - Systemic beta‑blockers: additive cardiovascular depression may occur. - Other ocular beta‑blocker preparations: risk of excessive beta‑blockade. - Additional prostaglandin analogs: increased ocular irritation. Moderate Interactions (Monitor Closely): - Anticholinergic eye drops: may reduce efficacy of pressure lowering. - Topical corticosteroids: potential increase in intra‑ocular pressure. - Beta‑agonist inhalers: monitor for reduced bronchodilation effect.